JP4061715B2 - Leukocyte separation and concentration method - Google Patents

Leukocyte separation and concentration method Download PDF

Info

Publication number
JP4061715B2
JP4061715B2 JP17819798A JP17819798A JP4061715B2 JP 4061715 B2 JP4061715 B2 JP 4061715B2 JP 17819798 A JP17819798 A JP 17819798A JP 17819798 A JP17819798 A JP 17819798A JP 4061715 B2 JP4061715 B2 JP 4061715B2
Authority
JP
Japan
Prior art keywords
bag
parent
blood
child
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP17819798A
Other languages
Japanese (ja)
Other versions
JP2000007571A (en
Inventor
昇司 川本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Corp
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Priority to JP17819798A priority Critical patent/JP4061715B2/en
Publication of JP2000007571A publication Critical patent/JP2000007571A/en
Application granted granted Critical
Publication of JP4061715B2 publication Critical patent/JP4061715B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、血液成分を含有する血液母液から白血球を分離し、濃縮する方法に関し、特に臍帯血、骨髄液、造血幹細胞および/または造血前駆細胞を含む白血球を、末梢血等から安全かつ無菌的に、効率よく、迅速に、そして経済的に採血し、分離し、濃縮する方法に関する。
【0002】
【従来の技術】
近年、臍帯血移植、骨髄移植或いは末梢血幹細胞移植による造血幹細胞移植が、再生不良性貧血や白血病などの血液疾患や、乳癌、精巣癌などの固形癌、或いは、リューマチなどの自己免疫疾患の根治療法として注目されつつある。
造血幹細胞移植を行うに当たっては、臍帯血、骨髄或いは末梢血等の血液母液から、造血幹細胞や造血前駆細胞を含む白血球を安全かつ無菌的に、効率良く、迅速に、そして、経済的に採取し、分離し、濃縮して、移植に備えておく必要がある。
また、血液母液の処理工程においては、移植される造血幹細胞数を厳密に把握するために、バッグ間で移注される血液成分の容量を把握しつつ処理作業を行う必要があるが、さらに、煩雑な作業を極力排除して作業効率を向上させるとともに、煩雑な作業に起因する製剤の汚染やコストアップを防止する必要がある。
【0003】
白血球を採血し、分離し、濃縮して凍結保存する方法としては、従来、血液母液を汚染させないよう厳重な注意の下に、注射器を用いて採血し、これを清潔な試験管に移し、これに赤血球沈降剤を添加して、軽遠心を行った後、上清のみを清潔な試験管に移し、凍害防止剤を添加して凍結保存する方法(試験管法)や、血液母液を採血バッグに採取し、赤血球沈降剤を添加して軽遠心を行った後、採血バッグのポートに白血球バッグの接続チューブのプラスチック針を接続して、採血バッグ中の濃縮された白血球層を白血球バッグに移注し、さらに遠心分離して上清を除去することによって、白血球層を適切な液量まで濃縮し、これに凍害防止などの処置を施して凍結保存する方法(バッグ法、WO96/17514号公報)などが知られている。
【0004】
一般に、造血幹細胞製剤等の生物製剤を製造する場合、生物製剤を滅菌することが極めて難しいことから、細菌による汚染を防ぐために、全ての製造工程をクローズドシステムにすることが必要とされる。
しかしながら、上記の方法は、試験管法では、血液母液等を注射器から試験管に移注する時、試験管を密封して凍結保存する時に、また、バッグ法では、血液等を採血バッグから他のバッグに移注する時に、血液等が直接外気に触れる工程を含んでおり、環境中に存在する細菌等により汚染される可能性があり、血液母液処理法としては、決して満足できるものではない。
従って、汚染の虞のない造血幹細胞製剤を製造するために、完全な無菌操作を前提に、血液母液の新しい処理方法の開発が望まれている。
【0005】
また、臍帯血移植時には、副作用の原因となることが懸念される赤血球の混入を無くするか、または、極力少なくすることが要求される。そこで、血液母液に、収容した親バッグを遠心分離後、底に開口した連結チューブから赤血球を抜く方法(いわゆるトップ&ボトム法、特公昭63−20144公報参照)を適用することが考えられる。この方法では、白血球層と赤血球層の界面を乱すことなく赤血球を除くことができるので赤血球の混入を少なくすることが出来る。また、無菌操作も、移植される造血幹細胞数を厳密に把握することも可能である。
しかしながら、上記トップ&ボトム法を単純に血液母液に適用したところ、理由は明らかでないが、赤血球の混入に関して必ずしも満足すべき結果が得られなかった。
【0006】
【発明が解決しようとする課題】
本発明は、如上の事情に鑑みてなされたもので、赤血球の混入や汚染を極力防止することができ、移植される造血幹細胞数を厳密に把握することのできる、無菌操作の可能な白血球の分離、濃縮方法を提供することを目的とする。
【0007】
【課題を解決するための手段】
本発明者は、鋭意検討の結果、軽遠心により分画された白血球層をさらに軽遠心して、血漿層と白血球濃厚液層に分画することにより上記の課題が解決されることを見出し、本発明を完成した。すなわち、本発明は、採血チューブを備えた親バッグに連結チューブを介して凍結バッグ、第1の子バッグ及び第2の子バッグが連結されたものであって、前記第1のバッグは前記親バッグの上部に取り付けられた連結チューブにより連結されてなり、前記親バッグには採取された臍帯血が収容してなる血液母液処理バッグを使用する、下記(a)〜()の工程を含んでなる白血球の分離、濃縮方法。()親バッグの底部が上になるように当該親バッグを倒立させて軽遠心または吊り下げ静置し、血液母液を上層の白血球層と下層の赤血球層に分離する。(親バッグの底部が上になるように倒立させたまま、下層の赤血球を第1の子バッグへと通じる連結チューブを経由して第1の子バッグに移注する。()赤血球の移注された第1の子バッグのみを、第1の子バッグへと通じる連結チューブを溶断して親バッグから分離する。()赤血球の除かれた親バッグの底部が下になるように当該親バッグを正立させて軽遠心し、白血球層を上層の血漿層と下層の白血球濃厚液層に分離する。()上層の血漿を、親バッグの容量が所定量になるまで第2の子バッグにゆっくり移注する。()白血球濃厚液を収容した親バッグに所定量の凍害防止剤を無菌的に添加する。()凍結防止剤を含む白血球濃厚液を凍結バッグに移注し、凍結バッグと連結する連結チューブを溶断して、凍結バッグを親バッグから分離する。の各工程を含んでなる。尚、工程()の前に、血液母液の採取された親バッグに所定量の赤血球沈降剤を添加してもよい。
【0008】
【発明の実施の形態】
次に本発明の実施例について図面に基づいて説明する。図1および図2は本発明で使用する血液母液処理バッグの例を示す説明図である。図1に示す血液母液処理バッグは、血液抗凝固剤を含む親バッグ1に、先端に採血針21を備えた採血チューブ2および、第1の子バッグ4、第2の子バッグ3、凍結バッグ5を接続したもので、採血チューブ2および、第1の子バッグ4、第2の子バッグ3、凍結バッグ5が全て天面で接続されている。ここで61、63、64、65は連結チューブ、73、74、75はクランプ、8は赤血球沈降剤を添加するためのポートである。また、図2に示す血液母液処理バッグは、図1において第2の子バッグ3および凍結バッグ5が底面で接続されたものである。
【0009】
図1に示す血液母液処理バッグを使用する場合について説明する。先ず、親バッグ1(容量200ml、血液凝固剤としてCPD液28ml収容)に採血チューブ2を通して臍帯血を採取する。血液母液を採取後、必要に応じて、親バッグ1にポート8を通して所定量の赤血球沈降剤(例えばDMSO5ml)を加えてもよく、また、ポート8から検査試料を採取してもよい。次に、この親バッグ1を、第1の子バッグ4、第2の子バッグ3、(容量150ml)と連結する連結チューブ61の取り付け部を下にして、すなわち、底部が上になるように倒立させて軽遠心する(工程)。これにより、比重の大きい赤血球層が親バッグ1の下層に沈降し、白血球層と赤血球層の間に明確な界面が形成され、血液母液が上層の白血球層と下層の赤血球層に分離される。尚、赤血球沈降剤を加えた場合、赤血球は短時間で沈降するが、充分な時間が許される場合は、赤血球沈降剤を加えなくても、さらには軽遠心をしないで吊り下げ静置しただけでも、赤血球が沈降して、血液母液を白血球層と赤血球層に分離することができる。
【0010】
次に、この親バッグ1を倒立させたまま、落差または分離スタンド(図示していない)を利用して、下層の赤血球を連結チューブ61、64を経由して第1の子バッグ4に移注する(工程)。この際、上清の白血球が混入しないように注意しつつ、静かに、ゆっくり移注する必要がある。この移注操作は、第1の子バッグ4に通じる連結チューブ61の親バッグ1への取付部が下になっているので、下層の赤血球を落差を利用して第1の子バッグ4に移注させた時に、白血球層と赤血球層の界面が水平を保ったまま乱れることなく下降する。従って、上層の白血球が赤血球層に混入することがないので、下層の赤血球の殆どを第1の子バッグ4に移送することができる。下層の赤血球の移注された第1の子バッグ4は、これに繋がる連結チューブ64を、例えばチューブシーラー(図示していない)等を用いて溶断して親バッグ1から分離し(工程)、廃棄する。
【0011】
次に赤血球が除かれ白血球層が残っている親バッグ1を、第1の子バッグ通じていた連結チューブ61の取り付け部を上にして、すなわち、底部が下になるように正立させて軽遠心する(工程)。これにより、目的の白血球が一層凝縮されて親バッグ1の下層に沈降し、上清は白血球を含まない血漿層になる。この上清の血漿層を分離スタンド(図示していない)を用いて、親バッグ1の重量を観察しながら(通常、親バッグ1を電子天秤に載せて重量を観察する)、落差により親バッグ1の容量が所定量になるまで第2の子バッグ3に静かにゆっくり移注する(工程)。ここで、造血幹細胞製剤の品質管理の最重要管理項目は、製剤中の白血球数の管理であり、そのため白血球の正確な容量管理が要求される。従って、本発明では、一旦第2の子バッグ3に移注された血漿を適当量親バッグ1に無菌的、かつ正確に戻すことができるように、血液母液処理バッグは親バッグ1と第2の子バッグ3が連結チューブ61、63で一体に接続されている。親バッグ1中の白血球数は、正確に所定容量に調整された白血球濃厚液の容量と、別途サンプリング白血球濃厚液の検査結果から、正確に算出することができる。また、工程においては、白血球が親バッグ1の底に沈降していることから、第2の子バッグ3への移注の際に発生する白血球の損失を極めて少なくすることができる。
【0012】
次に、この白血球濃厚液を収容した親バッグ1に、ポート8を通して無菌的に所定量の凍害防止剤を添加する(工程g)。添加される凍害防止剤の量は、例えばDMSOとデキストラン40を1:1の比率で混合した凍害防止剤の場合、白血球濃厚液20mlに対して5mlである。所定の容量に濃縮され、血液凝固剤および凍害防止剤を含んだ白血球濃厚液は、落差を利用して凍結バッグ5に移注し、全て移注し終わったら連結チューブ65を溶断して凍結バッグ5を親バッグ1から分離する(工程h)。得られた造血幹細胞製剤は、常法に従って液体窒素中に凍結保存される。
尚、図2に示す血液母液処理バッグを使用する場合については、工程bを除いて、図1に示す血液母液処理バッグを使用する場合と同様の操作を行えばよい。すなわち、図2に示す血液母液処理バッグを使用する場合には、工程bでは、血液母液処理バッグを倒立させる必要がなく、底を下にして正立した状態で軽遠心を行う。
【0013】
〔実施例1〜2〕出産後に娩出された胎盤および臍帯を滅菌済みトレーに入れて、これを清潔な臍帯血採血室に移した後、胎盤保持具と胎盤シーツを用いて臍帯側を下向きにしてスタンドに吊るし、臍帯の表面を良く消毒してから、図1(実施例1)および図2(実施例2)に示すような血液母液処理バッグを用いて、それぞれ本発明の方法に従い血液母液から白血球を分離、濃縮した後、白血球の収容された凍結バッグ5を常法に従って液体窒素中で凍結保存した。こうして得られた造血幹細胞製剤を各6単位ずつ用意し、それぞれ37℃の温水中で解凍して、無菌性および品質(有核細胞回収率、造血前駆細胞回収率および色)の検査を行ったところ、表1のような結果が得られた。なお、本試験においては、親バッグ1に血液母液を採血後、採血量の20%に相当するHES40(6%ヒドロキシエチル澱粉、菱山製薬(株)製)を、30mlシリンジを用いてポート8から親バッグ1に添加している。また、工程および工程における遠心は、それぞれ遠心力70Gで5分間、および遠心力400Gで5分間行った。また、無菌性の検査は血液検査用ボトル(ベクトン・ディキンソン社製)を用いて、35℃の好気的雰囲気および25℃の嫌気的条件下で2週間培養して行った。有核細胞数は自動血球数測定機(コールター社製)を用いて測定し、造血前駆細胞数はメチルセルローズ培地を用いて温度37℃、CO2 濃度5%の雰囲気で2週間培養し、顕微鏡下で観察計数した。赤血球混入の程度は製剤の赤色化(濃淡)の程度を目視で比較することにより判定した。
【0014】
〔比較例1〜3〕
出産後に娩出された胎盤および臍帯を滅菌済みトレーに入れて、これを清潔な臍帯血採血室に移した後、胎盤保持具と胎盤シーツを用いて臍帯側を下向きにしてスタンドに吊るし、臍帯の表面を良く消毒してから、従来のバッグ法(比較例1)および試験管法(比較例2)に従い、また図2に示すような血液母液処理バッグにバッグ法を適用して(比較例3)、それぞれ血液母液から白血球を分離、濃縮した後、白血球の収容された凍結バッグ5を常法に従って液体窒素中で凍結保存した。こうして得られた造血幹細胞製剤を各6単位ずつ用意し、それぞれ37℃の温水中で解凍して、試験例1と同様の検査を行ったところ、表1のような結果が得られた。
表から、本発明による造血幹細胞の品質が、従来法と比較して、無菌性、有核細胞回収率、造血前駆細胞回収率に優れ、赤血球の混入が少ないのがわかる。
【0015】
【表1】

Figure 0004061715
【0016】
【発明の効果】
以上説明してきたことから明らかなように、本発明の方法を採用することにより、血液母液から白血球製剤を安全かつ無菌的に効率よく分離し濃縮して、造血幹細胞製剤として凍結保存することができる。また、製剤に含まれる造血幹細胞数を精度良く管理することができ、さらに製剤中への赤血球の混入を極力防止することができる。
【図面の簡単な説明】
【図1】本発明で使用する血液母液処理バッグの一例を示す説明図である。
【図2】本発明で使用する血液母液処理バッグの他の例を示す説明図である。
【符号の説明】
1 親バッグ
2 採血チューブ
21 採血針
3、4 子バッグ
5 凍結バッグ
61、63、64、65 連結チューブ
73、74、75 クランプ
8 ポート[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method for separating and concentrating leukocytes from a blood mother liquor containing blood components, and in particular, leukocytes containing cord blood, bone marrow fluid, hematopoietic stem cells and / or hematopoietic progenitor cells can be safely and aseptically obtained from peripheral blood or the like. In particular, it relates to a method for efficiently, rapidly and economically collecting, separating and concentrating blood.
[0002]
[Prior art]
In recent years, hematopoietic stem cell transplantation by umbilical cord blood transplantation, bone marrow transplantation or peripheral blood stem cell transplantation is the cure for blood diseases such as aplastic anemia and leukemia, solid cancers such as breast cancer and testicular cancer, or autoimmune diseases such as rheumatism. It is getting attention as a therapy.
In performing hematopoietic stem cell transplantation, leukocytes containing hematopoietic stem cells and hematopoietic progenitor cells are collected safely and aseptically, efficiently, rapidly and economically from a blood mother liquor such as cord blood, bone marrow or peripheral blood. Need to be separated, concentrated and prepared for transplantation.
In the blood mother liquor treatment process, in order to accurately grasp the number of hematopoietic stem cells to be transplanted, it is necessary to carry out a treatment operation while grasping the volume of blood components transferred between bags, It is necessary to eliminate the cumbersome work as much as possible to improve the work efficiency, and to prevent the contamination and cost increase of the preparation due to the troublesome work.
[0003]
As a method of collecting leukocytes, separating, concentrating and cryopreserving them, conventionally, blood was collected using a syringe under strict care not to contaminate the blood mother liquor, and transferred to a clean test tube. After adding the erythrocyte sedimentation agent and performing a light centrifugation, transfer only the supernatant to a clean test tube, add a freezing protection agent and store it frozen (test tube method), or collect the blood mother solution in a blood collection bag After adding the erythrocyte sedimentation agent and performing light centrifugation, connect the plastic needle of the connection tube of the leukocyte bag to the port of the blood collection bag, and transfer the concentrated leukocyte layer in the blood collection bag to the leukocyte bag. Note that the leukocyte layer is concentrated to an appropriate liquid volume by centrifuging and removing the supernatant, and subjected to treatment such as prevention of freezing damage and the like, and then cryopreserved (Bag method, WO 96/17514) ) Etc. are known That.
[0004]
In general, when producing a biologic such as a hematopoietic stem cell preparation, it is extremely difficult to sterilize the biologic, and therefore it is necessary to make all the manufacturing processes a closed system in order to prevent contamination by bacteria.
However, in the test tube method, when blood mother liquor is transferred from a syringe to a test tube in the test tube method, when the test tube is sealed and frozen and stored, and in the bag method, blood or the like is removed from the blood collection bag. When transferring to a bag, it includes a process in which blood directly touches the outside air, which may be contaminated by bacteria present in the environment, and it is never satisfactory as a blood mother liquor treatment method. .
Therefore, in order to produce a hematopoietic stem cell preparation free from contamination, it is desired to develop a new method for treating blood mother liquor on the premise of complete aseptic operation.
[0005]
Further, at the time of umbilical cord blood transplantation, it is required to eliminate or minimize the mixing of erythrocytes, which may cause side effects. Therefore, it is conceivable to apply a method of extracting red blood cells from a connecting tube opened to the bottom after centrifuging the stored parent bag in the blood mother liquor (so-called top and bottom method, see Japanese Patent Publication No. 63-20144). In this method, since red blood cells can be removed without disturbing the interface between the white blood cell layer and the red blood cell layer, the mixing of red blood cells can be reduced. In addition, aseptic operation can also accurately grasp the number of transplanted hematopoietic stem cells.
However, when the top-and-bottom method was simply applied to the blood mother liquor, the reason was not clear, but satisfactory results were not always obtained with respect to red blood cell contamination.
[0006]
[Problems to be solved by the invention]
The present invention has been made in view of the above circumstances, and can prevent contamination and contamination of erythrocytes as much as possible, and can accurately ascertain the number of hematopoietic stem cells to be transplanted. An object is to provide a separation and concentration method.
[0007]
[Means for Solving the Problems]
As a result of intensive studies, the present inventor has found that the above-mentioned problems can be solved by further lightly centrifuging the leukocyte layer fractionated by light centrifugation and fractionating it into a plasma layer and a leukocyte concentrated liquid layer. Completed the invention. That is, the present invention is such that a freezing bag , a first child bag, and a second child bag are connected to a parent bag provided with a blood collection tube via a connecting tube, and the first bag is the parent bag. The following steps (a) to ( g ) are used, which are connected by a connecting tube attached to the upper part of the bag, and the parent bag uses a blood mother liquor treatment bag containing collected umbilical cord blood. A method for separating and concentrating leukocytes. And the parent bag was inverted so that the bottom of (a) parent bag is on top and light centrifugation or hanging standing, separating blood mother liquor in the upper leukocyte layer and a lower erythrocytes layer. ( B ) With the parent bag turned upside down, the lower red blood cells are transferred to the first child bag via a connecting tube leading to the first child bag. (C) separating only the first child bag and poured transfer of red blood cells from the parent bag blown the connection tube leading to the first child bag. ( D ) The parent bag is erected so that the bottom of the parent bag from which red blood cells have been removed is positioned downward, and lightly centrifuged to separate the leukocyte layer into an upper plasma layer and a lower leukocyte concentrated liquid layer. ( E ) Slowly transfer the upper plasma layer to the second child bag until the volume of the parent bag reaches a predetermined amount. ( F ) A predetermined amount of antifreezing agent is aseptically added to the parent bag containing the leukocyte concentrate. ( G ) The leukocyte concentrate containing the cryoprotectant is transferred to the freezing bag, the connecting tube connected to the freezing bag is melted, and the freezing bag is separated from the parent bag. Each process. A predetermined amount of erythrocyte sedimenting agent may be added to the parent bag from which the blood mother liquor has been collected before step ( a ).
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Next, embodiments of the present invention will be described with reference to the drawings. 1 and 2 are explanatory views showing an example of a blood mother liquor treatment bag used in the present invention. The blood mother liquor treatment bag shown in FIG. 1 includes a blood collection tube 2 provided with a blood collection needle 21 at the tip, a first child bag 4 , a second child bag 3 , a freezing bag, and a parent bag 1 containing a blood anticoagulant. 5, the blood collection tube 2, the first child bag 4 , the second child bag 3 , and the freezing bag 5 are all connected on the top surface. Here, 61, 63, 64 and 65 are connecting tubes, 73, 74 and 75 are clamps, and 8 is a port for adding an erythrocyte sedimentation agent. The blood mother liquor treatment bag shown in FIG. 2 is the one in which the second child bag 3 and the freezing bag 5 in FIG. 1 are connected at the bottom.
[0009]
The case where the blood mother liquor processing bag shown in FIG. 1 is used will be described. First, umbilical cord blood is collected through a blood collection tube 2 in a parent bag 1 (capacity 200 ml, containing CPD solution 28 ml as a blood coagulant). After collecting the blood mother liquid, if necessary, a predetermined amount of erythrocyte sedimentation agent (for example, DMSO 5 ml) may be added to the parent bag 1 through the port 8, and a test sample may be collected from the port 8. Next, the attachment portion of the connection tube 61 that connects the parent bag 1 to the first child bag 4 , the second child bag 3 , (capacity 150 ml) is turned down, that is, the bottom portion is up. Invert and lightly centrifuge (step a ). As a result, a red blood cell layer having a large specific gravity settles in the lower layer of the parent bag 1, a clear interface is formed between the white blood cell layer and the red blood cell layer, and the blood mother liquor is separated into the upper white blood cell layer and the lower white blood cell layer. When erythrocyte sedimentation agent is added, erythrocytes settle in a short time, but when sufficient time is allowed, even if erythrocyte sedimentation agent is not added, it can be suspended and left still without light centrifugation. However, red blood cells settle and blood mother liquor can be separated into white blood cell layers and red blood cell layers.
[0010]
Next, with the parent bag 1 turned upside down, the lower red blood cells are transferred to the first child bag 4 via the connecting tubes 61 and 64 using a head or a separation stand (not shown). (Step b ). At this time, it is necessary to infuse gently and slowly while taking care not to contaminate the leukocytes in the supernatant. In this transfer operation, since the attachment portion of the connection tube 61 leading to the first child bag 4 to the parent bag 1 is at the bottom, the lower red blood cells are transferred to the first child bag 4 using a head. When pouring, the interface between the white blood cell layer and the red blood cell layer descends without being disturbed while keeping the level. Accordingly, since the upper layer leukocytes are not mixed into the red blood cell layer, most of the lower layer red blood cells can be transferred to the first child bag 4. The first child bag 4 into which the lower red blood cells have been transferred is separated from the parent bag 1 by fusing the connecting tube 64 connected thereto, for example, using a tube sealer (not shown) or the like (step c ). ,Discard.
[0011]
Next, the parent bag 1 from which the red blood cells are removed and the leukocyte layer remains is erected with the attachment portion of the connecting tube 61 communicating with the first child bag 4 facing up, that is, with the bottom portion facing down. And lightly centrifuge (step d ). Thereby, the target white blood cells are further condensed and settled in the lower layer of the parent bag 1, and the supernatant becomes a plasma layer containing no white blood cells. Using a separation stand (not shown) for the plasma layer of the supernatant, while observing the weight of the parent bag 1 (usually observing the weight by placing the parent bag 1 on an electronic balance), Gently and slowly infuse the second child bag 3 until the volume of 1 reaches a predetermined amount (step e ). Here, the most important management item for the quality control of the hematopoietic stem cell preparation is the management of the number of white blood cells in the preparation, and therefore accurate white blood cell volume management is required. Therefore, according to the present invention, the blood mother liquor treatment bag is connected to the parent bag 1 and the second bag so that an appropriate amount of plasma once transferred to the second child bag 3 can be aseptically and accurately returned to the parent bag 1 . The child bag 3 is integrally connected by connecting tubes 61 and 63. The number of white blood cells in the parent bag 1 can be accurately calculated from the volume of the white blood cell concentrate adjusted to a predetermined volume and the test result of the separately sampled white blood cell concentrate. In step e , since leukocytes have settled on the bottom of the parent bag 1, the loss of leukocytes that occurs during transfer to the second child bag 3 can be extremely reduced.
[0012]
Next, a predetermined amount of antifreezing agent is aseptically added through the port 8 to the parent bag 1 containing the white blood cell concentrate (step g). For example, in the case of an antifreeze agent in which DMSO and dextran 40 are mixed at a ratio of 1: 1, the amount of the antifreeze agent added is 5 ml with respect to 20 ml of the leukocyte concentrate. The concentrated leukocyte solution that is concentrated to a predetermined volume and contains a blood coagulant and an antifreezing agent is transferred to the freezing bag 5 using a drop, and when the transfer is completed, the connecting tube 65 is melted to freeze the freezing bag. 5 is separated from the parent bag 1 (step h). The obtained hematopoietic stem cell preparation is stored frozen in liquid nitrogen according to a conventional method.
In the case of using the blood mother liquor treatment bag shown in FIG. 2, the same operation as that in the case of using the blood mother liquor treatment bag shown in FIG. That is, when the blood mother liquor processing bag shown in FIG. 2 is used, in step b, it is not necessary to invert the blood mother liquor processing bag, and light centrifugation is performed with the bottom upright.
[0013]
[Examples 1-2] Place the placenta and umbilical cord delivered after childbirth into a sterilized tray and transfer it to a clean umbilical cord blood collection room, and then place the umbilical cord side down using a placenta holder and placenta sheets. The blood mother liquor is hung on the stand and the surface of the umbilical cord is thoroughly disinfected, and then the blood mother liquor according to the method of the present invention is used using the blood mother liquor treatment bag as shown in FIG. 1 (Example 1) and FIG. 2 (Example 2). After separating and concentrating leukocytes, the freezing bag 5 containing leukocytes was cryopreserved in liquid nitrogen according to a conventional method. 6 units each of the thus obtained hematopoietic stem cell preparations were prepared, each thawed in warm water at 37 ° C., and tested for sterility and quality (nucleated cell recovery rate, hematopoietic progenitor cell recovery rate and color). However, the results shown in Table 1 were obtained. In this test, HES40 (6% hydroxyethyl starch, manufactured by Hishiyama Pharmaceutical Co., Ltd.) corresponding to 20% of the collected blood was collected from port 8 using a 30 ml syringe after blood mother liquor was collected in parent bag 1. It is added to the parent bag 1. Further, the centrifugation in the steps a and d was performed at a centrifugal force of 70 G for 5 minutes and at a centrifugal force of 400 G for 5 minutes, respectively. The sterility test was carried out using a blood test bottle (manufactured by Becton Dickinson) and cultured for 2 weeks under an aerobic atmosphere at 35 ° C. and an anaerobic condition at 25 ° C. The number of nucleated cells is measured using an automatic blood cell counter (manufactured by Coulter), and the number of hematopoietic progenitor cells is cultured for 2 weeks in an atmosphere of 37 ° C. and 5% CO 2 concentration using methylcellulose medium. Observed counts were made below. The degree of red blood cell contamination was determined by visual comparison of the redness (darkness) of the preparation.
[0014]
[Comparative Examples 1-3]
Place the placenta and umbilical cord delivered after childbirth into a sterilized tray and transfer it to a clean umbilical cord blood collection room. After thoroughly disinfecting the surface, according to the conventional bag method (Comparative Example 1) and test tube method (Comparative Example 2), the bag method was applied to a blood mother liquor treatment bag as shown in FIG. 2 (Comparative Example 3). ) After separating and concentrating leukocytes from each blood mother liquor, the freezing bag 5 containing leukocytes was cryopreserved in liquid nitrogen according to a conventional method. Six units each of the hematopoietic stem cell preparation thus obtained were prepared, each was thawed in warm water at 37 ° C. and tested in the same manner as in Test Example 1, and the results shown in Table 1 were obtained.
From the table, it can be seen that the quality of the hematopoietic stem cells according to the present invention is superior in sterility, nucleated cell recovery rate, and hematopoietic progenitor cell recovery rate and less erythrocyte contamination compared to the conventional method.
[0015]
[Table 1]
Figure 0004061715
[0016]
【The invention's effect】
As is clear from the above description, by adopting the method of the present invention, the leukocyte preparation can be safely and aseptically and efficiently separated and concentrated from the blood mother liquor and cryopreserved as a hematopoietic stem cell preparation. . In addition, the number of hematopoietic stem cells contained in the preparation can be controlled with high accuracy, and contamination of erythrocytes into the preparation can be prevented as much as possible.
[Brief description of the drawings]
FIG. 1 is an explanatory view showing an example of a blood mother liquor treatment bag used in the present invention.
FIG. 2 is an explanatory view showing another example of a blood mother liquor treatment bag used in the present invention.
[Explanation of symbols]
1 Parent bag 2 Blood collection tube 21 Blood collection needle 3, 4 Child bag 5 Freezing bag 61, 63, 64, 65 Connection tube 73, 74, 75 Clamp 8 port

Claims (1)

採血チューブを備えた親バッグの天面に連結チューブを介して凍結バッグ、第1の子バッグ及び第2の子バッグが連結されたものであって、
前記第1のバッグは前記親バッグの上部に取り付けられた連結チューブにより連結されてなり、
前記親バッグには採取された臍帯血が収容してなる血液母液処理バッグを使用する、下記(a)〜(g)の工程を含んでなる白血球の分離、濃縮方法。
(a)親バッグの底部が上になるように当該親バッグを倒立させて軽遠心または吊り下げ静置し、臍帯血液母液を上層の白血球層と下層の赤血球層に分離する。
(b)親バッグの底部が上になるように倒立させたまま、下層の赤血球を第1の子バッグへと通じる連結チューブを経由して第1の子バッグに移注する。
(c)赤血球の移注された第1の子バッグのみを、第1の子バッグへと通じる連結チューブを溶断して親バッグから分離する。
(d)赤血球の除かれた親バッグの底部が下になるように当該親バッグを正立させて軽遠心し、白血球層を上層の血漿層と下層の白血球濃厚液層に分離する。
(e)上層の血漿を、親バッグの容量が所定量になるまで第2の子バッグにゆっくり移注する。
(f)白血球濃厚液を収容した親バッグに所定量の凍害防止剤を無菌的に添加する。
(g)凍結防止剤を含む白血球濃厚液を凍結バッグに移注し、凍結バッグと連結する連結チューブを溶断して、凍結バッグを親バッグから分離する。
A freezing bag, a first child bag, and a second child bag are connected to the top surface of the parent bag equipped with a blood collection tube via a connection tube,
The first bag is connected by a connecting tube attached to the top of the parent bag,
A method for separating and concentrating leukocytes comprising the following steps (a) to (g), wherein a blood mother liquor treatment bag containing collected umbilical cord blood is used as the parent bag.
(A) The parent bag is turned upside down so that the bottom of the parent bag is up and left to stand by light centrifugation or hanging, and the umbilical cord blood mother liquor is separated into an upper leukocyte layer and a lower erythrocyte layer.
(B) The erythrocytes in the lower layer are transferred to the first child bag via a connecting tube that leads to the first child bag while the bottom of the parent bag is turned upside down.
(C) Only the first child bag into which the erythrocytes have been transferred is separated from the parent bag by fusing the connecting tube leading to the first child bag.
(D) The parent bag is erected so that the bottom of the parent bag from which red blood cells have been removed is down, and lightly centrifuged to separate the leukocyte layer into an upper plasma layer and a lower leukocyte concentrated liquid layer.
(E) Slowly transfer the upper plasma to the second child bag until the volume of the parent bag reaches a predetermined amount.
(F) A predetermined amount of antifreezing agent is aseptically added to the parent bag containing the leukocyte concentrate.
(G) The leukocyte concentrate containing the cryoprotectant is transferred to the freezing bag, the connecting tube connected to the freezing bag is melted, and the freezing bag is separated from the parent bag.
JP17819798A 1998-06-25 1998-06-25 Leukocyte separation and concentration method Expired - Fee Related JP4061715B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP17819798A JP4061715B2 (en) 1998-06-25 1998-06-25 Leukocyte separation and concentration method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17819798A JP4061715B2 (en) 1998-06-25 1998-06-25 Leukocyte separation and concentration method

Publications (2)

Publication Number Publication Date
JP2000007571A JP2000007571A (en) 2000-01-11
JP4061715B2 true JP4061715B2 (en) 2008-03-19

Family

ID=16044290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP17819798A Expired - Fee Related JP4061715B2 (en) 1998-06-25 1998-06-25 Leukocyte separation and concentration method

Country Status (1)

Country Link
JP (1) JP4061715B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527922A (en) * 2009-05-27 2012-11-12 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン Apparatus and method for producing blood products

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421348T1 (en) * 2001-12-05 2009-02-15 Caridianbct Inc METHOD AND DEVICE FOR SEPARATING BLOOD COMPONENTS
JP2006094934A (en) * 2004-09-28 2006-04-13 Asahi Kasei Medical Co Ltd Priming method of blood purification apparatus and blood purification apparatus
JP4594029B2 (en) * 2004-10-13 2010-12-08 テルモ株式会社 Blood component collection device
MX2007011218A (en) * 2005-03-23 2007-10-17 Biosafe Sa Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine.
JP2010193879A (en) * 2009-01-27 2010-09-09 Jms Co Ltd Method for controlling proliferation of umbilical cord blood hematopoietic stem cell and application thereof
CN111548992A (en) * 2020-05-28 2020-08-18 章毅 Method and device for preparing immune cells in blood in large scale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527922A (en) * 2009-05-27 2012-11-12 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン Apparatus and method for producing blood products

Also Published As

Publication number Publication date
JP2000007571A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
US5879318A (en) Method of and closed system for collecting and processing umbilical cord blood
RU2410125C2 (en) Complex system for collection, processing and transplantation of cell subpopulations, including mature stem cells, for regenerative medicine
Roos et al. [8] Purification and cryopreservation of phagocytes from human blood
Heaton et al. A comparative analysis of different methods for routine blood component preparation
CA2035929C (en) Pre-storage filtration of platelets
US9050422B2 (en) Stem and progenitor cell compositions recovered from bone marrow or cord blood; system and method for preparation thereof
JP5832591B2 (en) Composition of stem and progenitor cells recovered from bone marrow or umbilical cord blood, system and method for preparing them
JP2008520256A (en) Means, methods and apparatus for isolating liquids based on density
KR101307672B1 (en) Method for controlling propagation of umbilical cord blood hematopoietic stem cells and use thereof
JPH0720122A (en) Coagulation preventing solution, separating device using solution thereof and separating method
WO2004103440A1 (en) Container for serum production and method of regenerative medicine using the same
CN108849854B (en) Peripheral blood mononuclear cell cryopreservation method
US20070131612A1 (en) Cell separation method and apparatus
CN102321583B (en) Method for separating umbilical cord blood hematopoietic stem cell by gradient centrifugation
JP4061715B2 (en) Leukocyte separation and concentration method
AU687403B2 (en) Method and device for testing blood units for viral contamination
Zingsem et al. Cord blood processing with an automated and functionally closed system
Solves et al. Volume reduction in routine cord blood banking
RU2005137153A (en) METHOD AND DEVICE FOR BLOOD FRACTION
CN108588009A (en) A method of it detaches and activates the minimum embryonic-like stem cell of human peripheral
US5858642A (en) Closed system for processing cells
US20220409780A1 (en) Process for Preparing Blood Components and Biomedical Device
McMannis Use of the cobe 2991™ cell processor for bone marrow processing
JP2000288082A (en) Tube for washing and thickening sperm and method for washing and thickening sperm
RU2590688C2 (en) Method of producing suspension of nuclear cells of umbilical blood with standard concentration

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071217

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110111

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees